This article has Open Peer Review reports available.
Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung
© Proudfoot et al.; licensee BioMed Central. 2015
Received: 21 August 2014
Accepted: 13 February 2015
Published: 26 February 2015
H1N1 influenza viruses mutate rapidly, rendering vaccines developed in any given year relatively ineffective in subsequent years. Thus it is necessary to generate new vaccines every year, but this is time-consuming and resource-intensive. Should a highly virulent influenza strain capable of human-to-human transmission emerge, these factors will severely limit the number of people that can be effectively immunised against that strain in time to prevent a pandemic. An adjuvant and mode of administration capable of rendering ordinarily unprotective vaccine doses protective would thus be highly advantageous.
The carbohydrate mannan was conjugated to whole inactivated H1N1 influenza virus at a range of ratios, and mixed with it at a range of ratios, and various doses of the resulting preparations were administered to mice via the intranasal (IN) route. Serum immunity was assessed via antigen-specific IgG ELISA and the haemagglutination-inhibition (HI) assay, and mucosal immunity was assessed via IgA ELISA of bronchio-alveolar lavages.
IN-administered inactivated H1N1 mixed with mannan induced higher serum IgG and respiratory-tract IgA than inactivated H1N1 conjugated to mannan, and HIN1 alone. Adjuvantation was mannan-dose-dependent, with 100 μg of mannan adjuvanting 1 μg of H1N1 more effectively than 10 or 50 μg of mannan. Serum samples from mice immunised with 1 μg H1N1 adjuvanted with 10 μg mannan did not inhibit agglutination of red blood cells (RBCs) at a dilution factor of 10 in the HI assay, but samples resulting from adjuvantation with 50 and 100 μg mannan inhibited agglutination at dilution factors of ≥ 40. Both serum IgG1 and IgG2a were induced by IN mannan-adjuvanted H1N1 vaccination, suggesting the induction of humoral and cellular immunity.
Mixing 100 μg of mannan with 1 μg of inactivated H1N1 adjuvanted the vaccine in mice, such that IN immunisation induced higher serum IgG and respiratory tract IgA than immunisation with virus alone. The serum from mice thus immunised inhibited H1N1-mediated RBC agglutination strongly in vitro. If mannan similarly adjuvants low doses of influenza vaccine in humans, it could potentially be used for vaccine ‘dose-sparing’ in the event that a vaccine shortage arises from an epidemic involving a highly virulent human-to-human transmissable influenza strain.
Currently, H1N1 vaccines are administered unadjuvanted intramuscularly and rely on the induction of serum IgG to induce protection. Estimating the vaccine efficacy (VE) of this strategy in a broad sense is complicated by the fact that from year to year the strains chosen for inclusion match the actual emerging strains to varying degrees; thus data collected one year cannot be directly compared to data collected the next. Vaccination is clearly far from 100% efficacious, with a recent large-scale 'sentinel' study calculating an overall VE of 47% . Immunising with live attenuated virus at the site of influenza virus entry, i.e. intranasally (IN), has been investigated in humans and results suggest that a regime based on or including IN immunisation may enhance VE, and may be more effective in generating heterotypic immunity [2,3].
Recent threats of the potential large-scale emergence of human-to-human transmissible forms of virulent H5N1 (reviewed in Kaplan et al. ) and H7N9 (reviewed in Wu et al. ) avian influenza strains, and the actual emergence of widespread human-to-human transmissible variants of an H1N1 variant dubbed ‘swine-flu’ (reviewed in Dhama et al. ) have highlighted the need for a non-toxic, cost-effective dose-sparing influenza vaccine adjuvant. An adjuvant that substantially reduces the amount of influenza virus normally required for protective vaccination would allow for faster immunisation of potentially high-risk sections of the population such as children and asthmatics, against a rapidly emerging, highly virulent influenza strain.
In this study, we investigated the ability of mannan to adjuvant whole inactivated H1N1 (A/New Caledonia 20/1999) influenza virus in mice. Mannan is a non-toxic carbohydrate produced in most plants and yeasts, and it has been administered parentarally to over 200 humans as part of previous clinical trials in cancer, without adverse events [7-9]. Based on previous reports that IN immunisation of mice with mannan conjugated to antigen induces both mucosal IgA and serum IgG , mice were vaccinated via the intranasal route. Our initial studies focused on vaccination with preparations comprised of whole influenza virus conjugated to oxidised mannan, in an effort to target the virus directly to DCs, via the mannose receptor [11,12]. Surprisingly, while H1N1 conjugated to mannan was no more immunogenic than H1N1 alone, mixing free mannan with H1N1 yielded substantially greater serum IgG and IgA titres, and IgA titres in the lung.
After determining that extending the intervals between immunisations enhanced the induction of lung IgA, we then tested varying amounts of mannan mixed with a constant low dose of H1N1; while a small amount of mannan had proven unable to adjuvant a small amount of H1N1, we hypothesised that a large amount of mannan may be able to. Further, it was hypothesised that using the protracted immunisation schedule, substantial lung IgA and serum IgG may be induced after two immunisations, without the need for a third. These strategies proved successful, with two intranasal immunisations of 1 μg of H1N1 mixed with 100 μg of mannan inducing lung IgA, serum IgG1 and IgG2a, and serum immunity capable of neutralising the haemagglutination capacity of the virus in vitro.
Influenza virus and mice
Egg-grown H1N1 (A/New Caledonia/20/1999) virus purified by sucrose gradient, concentrated, and inactivated with ß-propiolactone was kindly provided by the WHO Collaborating Centre for Reference and Research on Influenza (North Melbourne, Australia). All mice were female BALB/c sourced from the Walter and Elisa Hall Institute (Melbourne, Australia), and were 8–10 weeks of age at first immunisation. All mouse-work was conducted at the Austin Hospital Animal Facility (Melbourne, Australia) in accordance with an animal ethics application approved by the Austin Animal Ethics Committee.
H1N1 mannan conjugates and H1N1 mannan mixes
Whole inactivated H1N1 was conjugated to oxidised mannan via the conjugation method described in Stambas et al. . Mannan (1 mL of 14 mg/mL) in 0.1 M phosphate pH 6.0 was oxidised with the addition of 0.1 M sodium periodate (100 μL in water) in the dark at 4°C for 1 hr. The mixture was quenched with 10 μL ethanediol and reacted for a further 30 min as before. The oxidised mannan mixture was passed through a PD10 column (GE Biosciences) pre-equilibrated with 0.05 M bicarbonate pH 9.0 to remove byproducts. The eluted 2 mL fraction of oxidised mannan (7 mg/mL) after void volume (2.5 mL) was collected. The resulting conjugate was used without further purification. In previous studies we have optimised the conjugation of mannan to recombinant cancer-associated antigens  as well as bacterial  and viral proteins. The periodate oxidation condition for mannan was chosen such that aldehyde residues are generated from only a fraction of oxidised mannose units of the mannan, without affecting its C-type lectin binding activity [14-17]. For a complex antigen such as a whole inactivated virus we expect the majority of conjugation of mannan aldehyde groups to take place only at the exposed amino groups, forming Schiff base linkages. To identify optimal conjugation conditions, various amounts of whole virus (36 μg, 18 μg and 9 μg) were separately reacted with 350 μg of oxidised mannan, and the resulting preparations were analysed by gel electrophoresis. The oxidised mannan-H1N1 conjugates were filter-sterilised and then aliquoted and stored at −20°C. The concentration of H1N1 was based on the total amount of H1N1 used for conjugation. Mixtures of H1N1 and mannan were generated by diluting the H1N1 stock (from 2.7 mg/mL) and the mannan stock (from 14 mg/mL) in sterile PBS, such that the desired dose of each was contained per 50 μL; the volume of each individual vaccination.
All immunisations were administered via the intranasal route. While completely anaesthetised (via methoxyfluorane inhalation) and held upright, 5-μL drops were gently pipetted alternately into each nostril. The total volume of every immunisation was standardised to 50 μL, regardless of H1N1 dose or mannan dose. All mannan used throughout the study was derived from Sacharomyces cerevisiae, and sourced from Sigma (product# M7504-5G).
H1N1 mannan conjugate vs. mannan mixture
To investigate the potential for mannan to adjuvant the induction of IgA, groups of 9 mice were then immunised three times (days 0, 10 and 17) with 10 μg of H1N1 either alone, conjugated to 100 μg of mannan or mixed with 100 μg of mannan. Serum was harvested from all mice 7 days after the final immunisation, and lung washes were performed on 5 mice from each group. All samples were assayed for anti-H1N1 IgA by ELISA.
Mannan mixture with extended immunisation intervals
We then assessed whether increasing the time between immunisations and delaying lung wash harvesting yielded greater respiratory tract IgA, as isotype conversion to IgA is known to occur over weeks, rather than days . A subgroup of mice was immunised with 10 μg of H1N1 mixed with 100 μg of mannan three times at 14-day intervals, and lung washes were collected 14 days after the final immunisation.
Increased mannan dose in H1N1 mixture
We then assessed whether a large amount of mannan could boost the immune response to a small amount of antigen. We also tested whether by using the previously investigated extended interval between immunisations (14 days), substantial serum IgG and lung IgA were induced in mice after two immunisations, negating the requirement for a third. Mice were immunised with 1 μg of H1N1 mixed with 10, 50 or 100 μg of mannan twice, 14 days apart. Fourteen days after the second immunisation, serum was harvested and assayed for anti-H1N1 IgG.
Serum and bronchio-alveolar-lavage collection
Serum was collected via retro-orbital bleed as described in Donovan et al. . Bronchio-alveolar-lavage (BAL) fluid was collected after mice were euthanised via an intraperitoneally-administered preparation consisting of 66 μL xylazil, 166 μL ketamine, and 266 μL saline. Tissue was removed to expose the upper trachea, and a small incision was made therein. With the aid if a blunt needle attached to a 1 mL syringe, 1 mL of PBS was gently flushed into the lungs, and drawn back out.
ELISA determination of antibody titres
ELISAs were performed using the HRP/TMB system. Plates were coated with whole inactivated H1N1 (A/New Caledonia/20/1999) at a concentration of 1 μg/mL. Total anti-H1N1 IgG was detected using directly HRP-conjugated rat anti-mouse-IgG (GE healthcare, product # RPN1231V) and IgG1, IgG2a and IgA were detected using biotin-labelled primary antibodies from Pharmingen (product numbers 553441, 553388 and 556978 respectively), and secondary streptavidin-HRP from GE healthcare (product #346480). End-titre was defined as the last value in the titration to remain above the corresponding control value, where the control was calculated as the mean OD values + 2SD of naive mouse serum samples (3–5 mice) at each titration point.
Haemagglutination inhibition assays
HI assays were performed according to standard protocols . Sera were pre-treated with receptor destroying enzyme (RDE) II (Deka Seiken Co. Ltd., Tokyo, Japan) at a ratio of 1:4 (v/v) at 37°C for 16 hrs, then the enzyme was inactivated by the addition of an equal volume of 54.4 mM tri-sodium citrate (Ajax Chemicals, Australia), and incubation at 56°C for 30 min. At room temperature, 25 μL of an A/New Caledonia/20/1999 virus preparation was added to 25 μL of the RDE-treated serum preparation, then this solution was titrated in two-fold dilutions in PBS from an initial serum:diluent ratio of 1:10 to a final ratio of 1:1280. Following a 1-hr incubation, 25 uL of a 1% (v/v) suspension of turkey RBCs was added to each well. Haemagglutination was assessed via standard methods , after 30 min. Where no neutralising antibodies were present RBC agglutination proceeded uninhibited, but where anti-haemagglutinin (HA) serum immunity had been generated, neutralising antibody bound to the HA protein, inhibiting its ability to agglutinate the RBCs. Titres were defined as the reciprocal of the highest dilution of serum where haemagglutination was prevented.
H1N1/oxidised-mannan conjugates (H1N1_OxMan)
Before the administration of mannan conjugates to mice, the most effective ratio of oxidised mannan:H1N1 with regard to conjugation efficiency was determined, as described in the Methods section, above. The ratio of 39 μg of inactivated H1N1 to 350 μg of oxidised mannan (Figure 1, lane 3) resulted in the most mannosylation as judged by the replacement of discrete viral protein bands with a smear, due to glycosylation with oxidised mannan, as described in Apostolopoulos et al.  (Figure 1).
Immunogenicity of H1N1_OxMan conjugates and H1N1 + mannan mixes in mice
Mucosal antibody responses to H1N1_OxMan conjugates and H1N1+ mannan mixes
Optimisation of the immunogenicity of H1N1 + mannan mixtures
To confirm that the antibody induced by mannan-adjuvanted H1N1 was likely to equate with in vivo protection, serum from the immunised mice was tested in an HI assay. Only serum from mice immunised with H1N1 adjuvanted with 50 or 100 μg of mannan was able to inhibit the ability of H1N1 to agglutinate turkey RBCs. In previous studies , a titre of ≥ 40 (indicated by the dashed line) correlated with 50% protection against experimental infection with partially attenuated challenge strains. In this study, no mice immunised with 1 μg H1N1 alone yielded HI titres of ≥ 40, while all mice immunised with 1 μg H1N1 + 100 μg of mannan yielded HI titres of ≥ 40 (p < 0.01, Fisher's exact test) (Figure 5b).
When the threat of an H5N1 pandemic emerged in 2005, the World Health Organisation (WHO) indicated that research investigating flu adjuvants was a high priority. Identifying an effective ‘dose-sparing’ adjuvant was deemed important due to the potential emergence of new strains (reviewed in Fisman et al. ) and the lag time involved in producing vaccine in live embryonated chicken eggs.
In this study, the dose sparing potential of mannan as an adjuvant for influenza was explored. The initial strategy of conjugating mannan to whole influenza virus was investigated based on previous observations suggesting that this may promote targeting of antigen to DCs via the mannose receptor [11,12]. However, while mannan-conjugated whole virus proved no more immunogenic that virus alone, unexpectedly, ‘free mannan’ adjuvanted whole virus significantly. As our initial studies were focused on mannan-influenza conjugates, the ratio of mannan to H1N1 included in the ‘control’ (mannan mixed) conditions was kept proportional to the amount used to derive the conjugates; mice receiving low doses of H1N1 received proportionally low amounts of mannan. However, once it was ascertained that mannan functioned as an adjuvant when mixed with (rather than conjugated to) whole influenza virus, we abandoned the conjugation-based mannan to antigen ratio, and confirmed that 100 μg of free mannan was able to adjuvant a single microgram of whole inactivated H1N1.
We investigated intranasal influenza vaccination as this has been shown to stimulate the mucosal immune response and generate secretory IgA at the site of infection . Encouragingly, in a large-scale multi-centre human trial comparing intranasal (FluMist®) and intramuscular (Sanofi Pasteur) immunisation against influenza infection, IN immunisation was more protective than intramuscular (IM) immunisation against naturally acquired infection in infants . Notably, the intranasal route is also more amenable to ‘self-administration’ (via a nasal spray) than an intramuscular injection, which may prove advantageous during a pandemic caused by a rapidly spreading newly emergent influenza strain. Should a ‘booster’ (i.e. a second vaccination) be required for example, this could be supplied to the vaccinee at the time of their first vaccination (or subsequently by a pharmacist), to be self-administered 2 weeks after the first vaccine. Under this scenario, the first vaccine could also conceivably actually be self-administered under the careful guidance of a health-care professional, to ensure that the vaccinee was confident and capable of self-administering any subsequently required boosters. In a ‘similar vein’, in remote or disadvantaged communities where infrastructure and health professionals are scarce, a vaccine that negates the use of needles and could be self-administered would conceivably be advantageous.
While it has previously been shown that IN administration of mannan-conjugated proteins generates antigen-specific IgA in the lung , this is the first demonstration of this using whole virus as antigen and free mannan as adjuvant. The contribution of H1N1-specific lung IgA to protection against a live influenza challenge is currently under investigation. Both IgG2a and IgG1 were induced by H1N1 + mannan in the present study, suggesting the induction of cellular as well as humoral immunity. This bodes well for the vaccine strategy, as it is widely held that the generation of effective ‘heterotypic’ (cross-strain) immunity will require induction of a functional T cell response. We are currently characterising the cellular immunity induced by immunisation with mannan + H1N1 via a series of short peptides derived from each of the core viral proteins.
To date we have been unable to definitively confirm that the mannose receptor is involved in the mechanism of adjuvantation by free mannan observed in the current study, and notably other innate receptors may also be involved . Nevertheless, the observation that conjugation is not required in the context of influenza adjuvantation is fortuitous with regard to regulatory and production considerations; it would conceivably be much easier to achieve compositional standardisation across batches of GLP-produced vaccine if ‘production’ merely entailed mixing two homogenous GLP products together. Further, mannan is an adjuvant well suited to en-masse vaccination as it is very cheap, non-proprietary, easy to sterilise, store and transport, and has proven to be non-toxic to humans when delivered parenterally in clinical trials collectively comprising > 200 patients [7-9].
The recent emergence of ‘swine flu’ (H1N1s) has reinforced the need for a dose-sparing influenza adjuvant. In Australia  and New Zealand , after the rate of the initial wave of H1N1s infections peaked (in approximately June/early July 2009) it then declined, but the overall incidence of new infections remained significant, to the extent that H1N1s actually ‘displaced’ the seasonal A(H1N1) strain that had previously been predicted would account for the majority of infections. Despite the initial characterisation and isolation of the H1N1s strain occurring in April 2009 , ‘growing up’ enough effective doses of the vaccine was by necessity time-consuming, which contributed to the fact that vaccine did not become available to the general public until almost 6 months later, in early October. Before it became clear that H1N1s posed no greater risk of mortality than historical variants of the H1N1 ‘human’ flu, the British Government evidently intended to immunise more than half of its entire population against H1N1s . This would have been a massive endeavour, the efficacy of which would have depended largely on the speed at which it could have been implemented, which would in turn have been limited by the rate of production of effective vaccine doses. Implementation of a dose-sparing influenza adjuvant that allowed, for example, a five to ten-fold reduction in the amount of virus constituting a protective dose would significantly reduce the time between isolating a potentially pandemic influenza strain, and generating enough virus to immunise the population en-masse.
Mannan successfully adjuvanted H1N1 vaccination in mice, rendering otherwise weakly immunogenic doses inductive of strong serum IgG, and IgA in the lung. As mannan is cheap, non-toxic, non-proprietary, abundant and easy to transport, it represents an attractive candidate adjuvant for rendering small doses of human influenza vaccines more immunogenic (‘dose sparing’) in the event of a pandemic involving a highly virulent and/or transmissible strain; the results of the current study in mice suggest that further studies in larger animals and/or humans are warranted.
This study was supported by an NHMRC ‘Special Pandemic Influenza Grant’ (#365240), a subsequent NHMRC ‘Development Grant’ (#488420), and by the Victorian Operational Infrastructure Support Program.
- Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006–2007. J Infect Dis. 2009;199:168–79.View ArticlePubMedGoogle Scholar
- Belshe RB, Gruber WC. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children. Philos Trans R Soc Lond B Biol Sci. 2001;356:1947–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA, Riggs MW, et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000–2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004;158:65–73.View ArticlePubMedGoogle Scholar
- Kaplan BS, Webby RJ. The avian and mammalian host range of highly pathogenic avian H5N1 influenza. Virus Res. 2013;178:3–11.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu YL, Shen LW, Ding YP, Tanaka Y, Zhang W. Preliminary success in the characterization and management of a sudden breakout of a novel H7N9 influenza A virus. Int J Biol Sci. 2014;10:109–18.View ArticlePubMedPubMed CentralGoogle Scholar
- Dhama K, Verma AK, Rajagunalan S, Deb R, Karthik K, Kapoor S, et al. Swine flu is back again: a review. Pak J Biol Sci. 2012;15:1001–9.View ArticlePubMedGoogle Scholar
- Karanikas V, Thynne G, Mitchell P, Ong CS, Gunawardana D, Blum R, et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother. 2001;24:172–83.View ArticleGoogle Scholar
- Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006;8:R27.View ArticlePubMedPubMed CentralGoogle Scholar
- Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res. 2006;12:869–77.View ArticlePubMedGoogle Scholar
- Stambas J, Pietersz G, McKenzie I, Cheers C. Oxidised mannan as a novel adjuvant inducing mucosal IgA production. Vaccine. 2002;20:1068–78.View ArticlePubMedGoogle Scholar
- Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V, et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol. 2008;38:424–36.View ArticlePubMedGoogle Scholar
- Tang CK, Sheng KC, Esparon SE, Proudfoot O, Apostolopoulos V, Pietersz GA. Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier. Biomaterials. 2009;30:1389–400.View ArticlePubMedGoogle Scholar
- Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci U S A. 1995;92:10128–32.View ArticlePubMedPubMed CentralGoogle Scholar
- Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine. 2000;18:2059–71.View ArticlePubMedGoogle Scholar
- Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol. 2000;30:1714–23.View ArticlePubMedGoogle Scholar
- Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine. 2000;18:3174–84.View ArticlePubMedGoogle Scholar
- Sheng KC, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology. 2006;118:372–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Rudin A, Johansson EL, Bergquist C, Holmgren J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun. 1998;66:3390–6.PubMedPubMed CentralGoogle Scholar
- Donovan J, Brown P. Blood collection. In: Coligan JE, Bierer BE, Margulies DH, Shevach EM, Strober W, Coico R, editors. Current Protocols in Immunology. New York: John Wiley & Sons; 2006. Chapter 1:Unit 1.7.Google Scholar
- WHO Collaborating Centers for Reference and Research on Influenza. Concepts and procedures for laboratory-based influenza surveillance. Washington D.C: U.S. Dept. of Health and Human Services; 1982.Google Scholar
- Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70:767–77.View ArticleGoogle Scholar
- Fisman D, Pandemic Influenza Outbreak Research Modelling Team (Pan-InfORM). Modelling an influenza pandemic: A guide for the perplexed. CMAJ. 2009;181:171–3.View ArticlePubMedGoogle Scholar
- Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis. 2007;196:1313–20.View ArticlePubMedGoogle Scholar
- Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685–96.View ArticlePubMedGoogle Scholar
- Kjaerup RM, Dalgaard TS, Norup LR, Bergman IM, Sørensen P, Juul-Madsen HR. Adjuvant effects of mannose-binding lectin ligands on the immune response to infectious bronchitis vaccine in chickens with high or low serum mannose-binding lectin concentrations. Immunobiology. 2014;219:263–74.View ArticlePubMedGoogle Scholar
- Kelly H, Grant K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill. 2009;14:pii.19288.Google Scholar
- Centers for Disease Control and Prevention (CDC). Surveillance for the 2009 pandemic influenza A (H1N1) virus and seasonal influenza viruses - New Zealand, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:918–21.Google Scholar
- Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children—Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:400–2.Google Scholar
- UK Government: Swine flu - what the government is doing. www.rsphealthcare.com/ 2009, last accessed May 2013.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.